An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
GE Healthcare’s Stress Agent Rapiscan (Regadenoson) Approved for use in Stress Cardiac Magnetic Resonance Imaging
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
GE Healthcare has received approval from the European Medicines Agency for the use of its stress agent Rapiscan in additional imaging modalities. Previously used in SPECT MPI for adults, Rapiscan is now also approved for Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET). This approval allows Rapiscan to aid in diagnosing coronary artery disease in patients unable to exercise, enhancing diagnostic capabilities and patient experience.
Positive
Approval for Rapiscan in MRI, CT, and PET expands its use in diagnosing coronary artery disease.
High diagnostic performance of stress CMR with sensitivity and specificity above 90%.
Rapiscan does not require weight or age adjustments, increasing its applicability among patients.
Negative
None.
Already used in Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) for adult patients, Rapiscan is now approved for use in stress Cardiac Magnetic Resonance Imaging (CMR)
Rapiscan, a pharmacological stress agent, is an alternative for patients who cannot exercise
CHALFONT ST GILES, England--(BUSINESS WIRE)--
GE Healthcare has announced that it has received approval from the European Medicines Agency (EMA) for additional imaging modalities for its stress agent Rapiscan (Regadenoson). Already an established pharmacological stress agent in SPECT MPI for adult patients, Rapiscan is now approved for use in Magnetic Resonance Imaging (MRI) as well as Computed Tomography (CT) and Positron Emission Tomography (PET).1
Rapiscan simulates the effects of exercise in the hearts of adult patients unable to exercise and is used to aid the diagnosis of coronary artery disease (CAD). The approval for additional imaging modalities will enable Rapiscan to be used with an MR contrast agent in stress CMR to assess the function and blood flow of the heart, enabling radiologists/cardiologists to perform a single stress/rest/MRI protocol.
Stress CMR has shown high diagnostic performance (sensitivity and specificity of 90% and above) compared to gold standard invasive imaging for coronary artery disease and is recommended for use in the 2019 European Society of Cardiology guidelines for the diagnosis and management of chronic coronary syndromes, along with other non-invasive diagnostic tests, such as stress SPECT MPI.2
Rapiscan can be used across a broad spectrum of patients as it does not require weight and age-based modifications or an infusion pump.
Dr Gianluca Pontone, Director of Cardiovascular Imaging Department, Monzino Cardiology Center at University of Milan said: “Our experience with Rapiscan in stress MR was very positive. We found it easy to use and very effective in helping to speed up the entire examination which was a key factor for us as was the high level of tolerance amongst patients.”
Dr Mark Hibberd, Chief Medical Officer at GE Healthcare Pharmaceutical Diagnostics, said: “Market authorisation of the additional imaging modalities for Rapiscan could make it easier for more patients, who are unable to exercise, to have this stress test and aid radiologists and cardiologists in making assessments.”
GE Healthcare has the commercial rights to promote Rapiscan excluding US, Mexico and Canada.
GE Healthcare Pharmaceutical Diagnostics imaging agents support three patient procedures every second worldwide across MRI, X-ray/CT and nuclear medicine imaging. Its portfolio of cardiology products aims to support diagnosis and monitoring throughout the cardiac care pathway and aid treatment decisions across multiple pathologies with products available for use in interventional angiography laboratories, and in CT, MRI, Echocardiography and SPECT imaging.
About GE Healthcare:
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 47,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.
1 Rapiscan (regadenoson) Summary of Product Characteristics (EN), GE Healthcare, December 2021.
2 Danad I et al. Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis. Eur Heart J 2017; 38(13): 991–8.
Knuuti J et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41(3): 407–77
GE Healthcare received approval from the European Medicines Agency for Rapiscan to be used in Magnetic Resonance Imaging, Computed Tomography, and Positron Emission Tomography.
How does Rapiscan benefit patients unable to exercise?
Rapiscan simulates exercise effects on the heart, allowing patients who cannot exercise to undergo stress testing for coronary artery disease diagnosis.
What is the diagnostic performance of stress CMR using Rapiscan?
Stress CMR with Rapiscan shows a diagnostic performance of sensitivity and specificity above 90% compared to invasive imaging.
Which company announced the approval of Rapiscan?
The approval of Rapiscan was announced by GE Healthcare.
What is the significance of Rapiscan's recent approval?
The approval increases the application of Rapiscan in cardiac imaging, enhancing diagnostic options for patients unable to perform physical stress tests.
